UNIQURE Aktie

>UNIQURE Aktienkurs

19.65 EUR +3.6% (Tradegate)

Ask: 19.955 EUR / 90 Stück

Bid: 19.47 EUR / 90 Stück

Tagesumsatz: 4625 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

UNIQURE Aktie über LYNX handeln

Intraday

1 Jahr

>UNIQURE Performance

1 Woche: -10,9%

1 Monat: +7,4%

3 Monate: -61,4%

6 Monate: +65,5%

1 Jahr: +45,4%

laufendes Jahr: -5,6%

>UNIQURE Aktie

Name:

UNIQURE N.V. EO -,05

Land:

Niederlande

Sektor:

Gesundheit

ISIN/ Wkn:

NL0010696654 / A1XDTV

Symbol/ Ticker:

UQ1 (Frankfurt) / QURE (NASDAQ)

Kürzel:

FRA:UQ1, ETR:UQ1, UQ1:GR, NASDAQ:QURE

Index:

Webseite:

https://www.uniqure.com/

Profil:

uniQure N.V. is a biopharmaceutical company specia..
>Volltext..

Marktkapitalisierung:

1167.45 Mio. EUR

Unternehmenswert:

1028.79 Mio. EUR

Umsatz:

13.58 Mio. EUR

EBITDA:

-152.53 Mio. EUR

Nettogewinn:

-202.74 Mio. EUR

Gewinn je Aktie:

-3.78 EUR

Schulden:

458.39 Mio. EUR

Liquide Mittel:

514.77 Mio. EUR

Operativer Cashflow:

-132.75 Mio. EUR

Bargeldquote:

6.9

Umsatzwachstum:

-47.72%

Gewinnwachstum:

6.84%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 804.802 USD.

Suchwörter:

UNIQURE

Letzte Datenerhebung:

18.01.26

>UNIQURE Kennzahlen

Aktien/ Unternehmen:

Aktien: 61.6 Mio. St.

Frei handelbar: 92.18%

Leerverk. Aktien: 19.26%

Rückkaufquote: -30.23%

Mitarbeiter: 209

Umsatz/Mitarb.: 0.11 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 134.39%

Bewertung:

KGV: -

KGV lG: -

KUV: 81.61

KBV: 6.11

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -14.37%

Gewinnmarge: -1492.9%

Operative Marge: -1225.66%

Managementeffizenz:

Gesamtkaprendite: -30.65%

Eigenkaprendite: -165.27%

>UNIQURE Peer Group

Es sind 15 Aktien bekannt.

>UNIQURE Chart & Kurs - NASDAQ

>UNIQURE News

17.01.26 - 17:51	Notice of QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm (PR Newswire)
	RADNOR, Pa., Jan. 17, 2026 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) ("uniQure"). On November 3, 2025, uniQure......

15.01.26 - 03:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Uniqure im Wert von 630483 USD (Insiderkauf)
	Gut, Robert - Aufsichtsrat - Tag der Transaktion: 2026-01-12...

13.01.26 - 02:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Uniqure im Wert von 174319 USD (Insiderkauf)
	Kaye, Jack - Aufsichtsrat - Tag der Transaktion: 2026-01-09...

09.01.26 - 19:57	uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT‑130 Approval Pathway (Benzinga)
	uniQure N.V. (NASDAQ:QURE) shares are popping on Friday after the company said the FDA will review the data package for AMT‑130, its gene therapy for Huntington's disease, with a Type A meeting now scheduled. read more...

09.01.26 - 14:09	uniQure gains as FDA sets up meeting on gene therapy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.01.26 - 13:42	FDA-Gespräch zu Huntington-Therapie beflügelt uniQure-Aktie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

09.01.26 - 13:09

uniQure Announces Type A Meeting Scheduled with FDA (GlobeNewswire EN)

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Biologics License Application (BLA) data package to support accelerated approval of AMT-130, the Company's investigational gene therapy for the treatment of Huntington's disease....

08.01.26 - 22:48	QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm (PR Newswire)
	RADNOR, Pa., Jan. 8, 2026 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) ("uniQure"). On November 3, 2025, uniQure issued......

30.12.25 - 03:42	QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm (PR Newswire)
	RADNOR, Pa., Dec. 29, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) ("uniQure"). On November 3, 2025, uniQure......

23.12.25 - 21:33	QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm (PR Newswire)
	RADNOR, Pa., Dec. 23, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) ("uniQure"). On November 3, 2025, uniQure......

17.12.25 - 02:57	QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm (PR Newswire)
	RADNOR, Pa., Dec. 16, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) ("uniQure"). On November 3, 2025, uniQure......

16.12.25 - 19:21	What′s Going On With uniQure Stock On Tuesday? (Benzinga)
	uniQure shares slid nearly 31% in a month as the FDA raised concerns over whether AMT-130 Phase 1/2 data can support approval. read more...

10.12.25 - 23:39	QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm (PR Newswire)
	RADNOR, Pa., Dec. 10, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) ("uniQure"). On November 3, 2025, uniQure......

04.12.25 - 22:51	QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm (PR Newswire)
	RADNOR, Pa., Dec. 4, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) ("uniQure"). On November 3, 2025, uniQure issued......

04.12.25 - 15:06	uniQure stock falls after FDA′s notes on pre application of AMT-130 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.12.25 - 14:18	uniQure-Aktie stürzt ab: FDA-Feedback deutet auf unzureichende Daten für Huntington-Therapie hin (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

04.12.25 - 13:09

uniQure Provides Regulatory Update on AMT-130 for Huntington′s Disease (GlobeNewswire EN)

LEXINGTON, Mass. and AMSTERDAM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a pre-Biologics License Application (BLA) meeting held on October 29, 2025 to discuss the application for AMT-130, an investigational gene therapy for Huntington's disease (HD). ...

28.11.25 - 17:48	QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm (PR Newswire)
	RADNOR, Pa., Nov. 28, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) ("uniQure"). On November 3, 2025, uniQure......

22.11.25 - 17:42	QURE Investigation Notification: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm (PR Newswire)
	RADNOR, Pa., Nov. 22, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) ("uniQure"). On November 3, 2025, uniQure......

20.11.25 - 16:06	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE (PR Newswire)
	NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Leichenwäscher gibt keine Gewähr für das Paradies. - Sprichwort Afrika

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram